Watch now! IAVI's Dr. Gaudensia Mutua and HJF Medical Research International's Dr. Abdulwasiu Bolaji Tiamiyu were recently interviewed by NTAi News about IAVI C105, the first #LassaFever vaccine candidate to enter a Phase 2 clinical trial. They discussed African scientists' and communities' leading roles in developing this vaccine – plus, how these efforts drive forward global health progress. ▶ https://lnkd.in/ey23GxM3 CEPI (Coalition for Epidemic Preparedness Innovations)
IAVI
Research Services
New York, NY 33,883 followers
Translating science into global health impact.
About us
Translating scientific discoveries into affordable, globally accessible public health solutions. IAVI is a non-profit that develops vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases.
- Website
-
www.iavi.org
External link for IAVI
- Industry
- Research Services
- Company size
- 201-500 employees
- Headquarters
- New York, NY
- Type
- Nonprofit
- Founded
- 1996
- Specialties
- AIDS vaccine, research and development, product development partnership, HIV/AIDS, vaccine development, global health, capacity strengthening, clinical trials, and scientific research
Locations
-
Primary
125 Broad St
9th Floor
New York, NY 10004, US
Employees at IAVI
Updates
-
IAVI reposted this
🎉Keynote panel announcement! We're excited to announce another panel with more key speakers! This panel will explore the challenges and strategies related to the uptake of vaccines amidst rapid vaccine development. Our panelists are: ⭐Hanna Nohynek, Chief Physician, National Institute for Health and Welfare ⭐Marco Cavaleri, Head of Biological Health Threats and Vaccines Strategy, European Medicines Agency ⭐Marion F. Gruber, Ph.D., MS, Vice President of Public Health and Regulatory Affairs, IAVI ⭐Thomas Waite, Deputy Chief Medical Officer, Department of Health and Social Care ⭐Sibilia Quilici, Executive Director, Vaccines Europe For speaking opportunities, apply here! https://buff.ly/45Tkd19 or get in touch with Anna ([email protected])💫 Want to see this keynote panel live? Register now! https://buff.ly/4eWoapE 📆Pre-Congress Workshops | 28 October 2024 📍Catalonia Barcelona Plaza 📆Main Congress | 29 – 31 October 2024 📍Fira de Barcelona Montjuic #WVCEU #VaccineDevelopment #VaccineInnovation #HealthcareInnovation #Vaccines
-
-
IAVI reposted this
Join us at the next TB Vaccine Advocacy Roadmap (TB Vax ARM) webinar on Tuesday 16 July to hear insights on: 💉 Inclusion of new TB vaccines in Gavi, the Vaccine Alliance Vaccine Investment Strategy ⏩ The World Health Organization's TB Vaccine Accelerator Council 🦠 Advocating for TB vaccines at the High-Level Meeting on AMR 🔗 Register at https://lnkd.in/eKSa7SXs
-
-
IAVI and our partners UNITAID, Medecins Patent Pool, and Wellcome are proud to announce a new publication providing insight into novel approaches that can expand access to monoclonal antibodies for those in low- and middle- income countries. https://lnkd.in/enVkPsF7
-
Saturday, July 6, is World Zoonoses Day! On this date in 1885, the first rabies vaccine was administered. This year, IAVI is marking progress toward a vaccine for a globally important zoonotic illness: Lassa fever. A new website feature highlights some recent publications and announcements marking some exciting steps forward: 🔵 An updated Lassa research roadmap in The Lancet co-authored by Swati Gupta, IAVI’s head of emerging infectious diseases. 🔵 The announcement of the start of vaccinations in a Phase 2 clinical trial of IAVI’s Lassa fever vaccine candidate in Liberia. 🔵 A commentary on African leadership in Lassa vaccine development by Dr. Gaudensia Mutua, a medical monitor on our Lassa trials. Read and share the feature to help IAVI and our partners celebrate these developments!👇 #globalhealth #lassafever #vaccineswork #partnerships #outsmartepidemics CEPI (Coalition for Epidemic Preparedness Innovations) | Global Health EDCTP3 | National Institute of Allergy and Infectious Diseases (NIAID) | Viral Hemorrhagic Fever Consortium | Batavia Biosciences
World Zoonoses Day 2024: IAVI celebrates progress in Lassa vaccine development
https://www.iavi.org
-
IAVI reposted this
You are invited to a webinar convened by the African Vaccine Manufacturing Initiative (AVMI) and IAVI to discuss Optimising Vaccine Strategy with Socio - Behavioural Insights. This session aims to explore how understanding social and behavioural factors can enhance vaccine acceptance and distribution across Africa. Aligning with AVMI's mission, we'll delve into key challenges affecting vaccine uptake, such as cultural beliefs, trust issues, and access barriers. Through interactive discussions, case studies, and collaborative problem-solving exercises, participants will gain practical strategies for improving vaccine acceptance and implementing effective awareness campaigns. By the end of the webinar, it is anticipated that attendees will have actionable insights to optimise vaccine strategies in their regions, furthering AVMI's vision of making Africa a key player in global vaccine development and manufacture. The webinar will be led by IAVI's Director of Socio-Behavioural Research Yvonne Wangũi Machira and moderatored by William Ampofo, AVMI Executive Director. 📅 9 July 2024 🕑 14:00 – 15:00 SAST 📌 Register via the Zoom Link: https://lnkd.in/d8DaQDD2 #vaccineacceptance #vaccinestrategies #vaccinesforafrica
-
-
📢 “Many EIDs are being underestimated,” stated Swati Gupta, Ph.D., in a recent interview with Global Health Hub Netherlands. As IAVI’s Vice President and Head of Emerging Infectious Diseases, Gupta is attuned to the public health challenges posed by the global spread of #EIDs — including Lassa fever, Marburg virus, and Sudan Ebolavirus. According to Gupta, these diseases cannot be tackled without addressing broader pandemic preparedness initiatives and healthcare equity concerns. The interview further highlights IAVI’s efforts to promote local capacity strengthening and develop globally accessible vaccines, with the support of the Dutch Ministry of Foreign Affairs and the Dutch Global Health Hub. Read the full article to learn more: https://ow.ly/vrjC50SqtWS
IAVI: Making Safe, Innovative Health Solutions a Global Public Good
english.globalhealthhub.nl
-
#HIVprevention initiatives must represent and center LGBTQIA communities, researchers, advocates, and policymakers—this #Pride and always. 🌈 Through the ADVANCE partnership (USAID), IAVI supports key research and policy efforts impacting LGBTQIA communities across sub-Saharan Africa. Check out and amplify these resources. ⬇️ - National Guidance on Integrating Mental Health (2022): https://ow.ly/683350SprPB - Key Population Size Estimation (KPSE) in Kenya (2022): https://ow.ly/CfnJ50SprPF - JIAS Supplement: Engagement of African men and transgender women who have sex with men in HIV research (2020): https://ow.ly/MgzG50SprPz - National Implementation Guidelines for HIV and STI Programming Among Young Key Populations (2018): https://ow.ly/eQqY50Sps4n - National Violence Prevention and Response Protocol - Kenya (2017): https://ow.ly/Nx5V50Sps7Z - Respect, Protect, Fulfill: MSM Research Guidance (2015): https://ow.ly/r5hy50SprPE
-
-
IAVI congratulates our partner PREVAIL in Liberia on starting vaccinations in a Phase 2a clinical trial of IAVI’s Lassa fever vaccine candidate! PREVAIL expects to enroll 204 participants at the JFK Hospital in Monrovia, Montserrado County. This Phase 2a study is the next step of IAVI and CEPI (Coalition for Epidemic Preparedness Innovations)'s Lassa vaccine development partnership, launched in 2018. Importantly, it’s the most advanced clinical trial of a Lassa vaccine to date. Vaccinations are ongoing in Nigeria, and we expect to enroll additional participants in Ghana. Lassa fever is one of the pathogens in the World Health Organization R&D Blueprint list of epidemic threats needing urgent R&D action. No vaccine is available for this viral hemorrhagic illness, and treatment is limited, despite seasonal outbreaks and high case fatality rates. Read more: https://lnkd.in/dFwNeHrf
Liberia: PREVAIL Begins Vaccinations in the Phase 2a Lassa Fever Vaccine Study - Independent Probe Newspaper
https://independentprobe.com
-
IAVI and partners in the EDCTP-funded UPTAKE study are proud to share a the first publication from Kenneth R. Katumba. Kenneth is based at MRC/UVRI & LSHTM Uganda Research Unit and one of two UPTAKE PhD candidates enrolled at London School of Hygiene and Tropical Medicine, U. of London. The paper, 'Understanding the contexts in which female sex workers sell sex in Kampala, Uganda: a qualitative study' discusses the value of researchers and implementers in considering the differences in the contexts, challenges, and risks of where women sell sex to design innovative interventions and programs that reach and include all women. 📰 Read it at: https://lnkd.in/e6irR3pE Busara | KAVI Institute of Clinical Research (KAVI-ICR) | Global Health EDCTP3
-